FDA Panel Mixed on King Pharmaceuticals®, Inc., Pain Therapeutics Drug; FDA Scheduled to Act By December 10 Under Six-Month Priority Review

Nov. 13 (Bloomberg) -- Pain Therapeutics Inc. and King Pharmaceuticals Inc.'s experimental pain pill Remoxy is less susceptible to abuse than Purdue Pharma LP's OxyContin, members of a U.S. panel said, suggesting the drug will win approval.